	US 11,718,664 B2
	Methods for reducing migraine frequency in a subject in need thereof
Rami Burstein, Chesnut Hill, MA (US)
Assigned to Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed by Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed on Aug. 18, 2020, as Appl. No. 16/996,581.
Application 16/996,581 is a continuation of application No. 15/909,895, filed on Mar. 1, 2018, granted, now 10,766,952.
Claims priority of provisional application 62/516,406, filed on Jun. 7, 2017.
Claims priority of provisional application 62/514,346, filed on Jun. 2, 2017.
Claims priority of provisional application 62/490,953, filed on Apr. 27, 2017.
Claims priority of provisional application 62/466,158, filed on Mar. 2, 2017.
Prior Publication US 2020/0385449 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61P 25/06 (2006.01); A61K 9/00 (2006.01); A61P 43/00 (2006.01); A61P 29/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 25/06 (2018.01); A61P 29/00 (2018.01); A61P 43/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A method for reducing migraine frequency in a subject suffering from migraine comprising:

a) determining or having determined whether the subject exhibits allodynia and/or hyperalgesia during an interictal phase of a migraine, and

b) administering an anti-CGRP antagonist antibody or an anti-CGRP receptor antibody that blocks, inhibits, suppresses, or reduces the calcitonin gene related peptide (CGRP) pathway to the subject that does not exhibit signs of allodynia and/or hyperalgesia during the interictal phase of the migraine.